Study 201312: A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects With a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Asthma
- Sponsors GlaxoSmithKline
- 05 Aug 2017 This trial has been completed in Germany.
- 21 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 29 Sep 2017.
- 02 Apr 2017 Trial has been completed in Spain.